Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ruderman, E. M.
Right arrow Articles by Weinblatt, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruderman, E. M.
Right arrow Articles by Weinblatt, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The British Journal of Rheumatology, Vol 36, 210-213, Copyright © 1997 by British Society for Rheumatology

ORIGINAL PAPERS

Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis

EM Ruderman, JM Crawford, A Maier, JJ Liu, EM Gravallese and ME Weinblatt
Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

A retrospective review was performed on 188 autopsied cases of rheumatoid arthritis at our institutions during 1958-1985, prior to the widespread use of methotrexate. Hepatic histology was reported in 182 cases. All available microscopic liver slides from cases in which the autopsy report described portal tract inflammation, fibrosis, cirrhosis, tumour, amyloid, vasculitis, or infections involving the liver were examined and graded by a hepatic pathologist blinded to the original diagnosis, along with a representative sample of cases with reports describing fatty change or no hepatic pathologic abnormalities. Ninety normal and abnormal cases were reviewed from the 182 for which hepatic histology was available. Fifteen cases of diffuse fibrosis were identified upon blinded review. Two cases were graded as severe fibrosis (grades 3 or 4 on a scale of 0-4) without an identifiable pathologic cause, in both of which the liver disease was suspected premortem (alcohol abuse and viral hepatitis). Although the incidence of fibrosis in this series is slightly higher than that previously described, serious fibrotic liver disease was rare. These results support the current practice of limiting pre-treatment liver biopsies prior to methotrexate therapy to patients with suspected liver disease.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
B. N. Cronstein
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Pharmacol. Rev., June 1, 2005; 57(2): 163 - 172.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. G. Feagan, R. N. Fedorak, E. J. Irvine, G. Wild, L. Sutherland, A. H. Steinhart, G. R. Greenberg, J. Koval, C. J. Wong, M. Hopkins, et al.
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
N. Engl. J. Med., June 1, 2000; 342(22): 1627 - 1632.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Richard, S. Guerret, F. Gerard, J. G. Tebib, and E. Vignon
Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system
Rheumatology, January 1, 2000; 39(1): 50 - 54.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.